LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

Search

Catalent Inc

Geschlossen

Branche Gesundheitswesen

55.12 -0.05

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

54.87

Max

55.26

Schlüsselkennzahlen

By Trading Economics

Einkommen

105M

-101M

Verkäufe

96M

1.1B

EPS

0.21

Gewinnspanne

-9.018

Angestellte

17,800

EBITDA

83M

105M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+7.55 upside

Dividenden

By Dow Jones

Nächstes Ergebnis

27. Aug. 2024

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

296M

10B

Vorheriger Eröffnungskurs

55.17

Vorheriger Schlusskurs

55.12

Nachrichtenstimmung

By Acuity

50%

50%

108 / 370 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

Catalent Inc Chart

Ähnliche Nachrichten

3. Mai 2024, 13:51 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Seeks More Info On $16.5 Billion Novo/Catalent Deal

5. Feb. 2024, 14:50 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Holdings to Buy Catalent for $11.5 Billion in Cash -- 4th Update

5. Feb. 2024, 13:11 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Holdings to Buy Catalent for $11.5 Billion in Cash -- 3rd Update

5. Feb. 2024, 12:09 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Holdings to Buy Catalent in $16.5 Billion Deal -- 2nd Update

5. Feb. 2024, 11:38 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Buys Manufacturing Sites as Part of Novo Holdings' Acquisition of Catalent

5. Feb. 2024, 11:31 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Holdings Buying Catalent in $16.5 Billion Deal -- Update

5. Feb. 2024, 11:23 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Holdings Buying Catalent in $16.5 Billion Deal

23. März 2024, 13:00 UTC

Top News

U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies -- Heard on the Street -- WSJ

5. Feb. 2024, 18:04 UTC

Akquisitionen, Fusionen, Übernahmen

Wegovy Maker to Boost Production Capacity With Multibillion-Dollar Deal -- WSJ

5. Feb. 2024, 17:27 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Makes the Latest Big Pharma Deal. Why More Are Coming. -- Barrons.com

5. Feb. 2024, 15:36 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk To Up Production Capacity As Parent Buys Catalent -- IBD

5. Feb. 2024, 11:38 UTC

Akquisitionen, Fusionen, Übernahmen

Catalent Stock Jumps on $16.5 Billion Sale to Controlling Shareholder of Ozempic Maker Novo Nordisk -- Barrons.com

5. Feb. 2024, 11:15 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk's Controlling Shareholder To Buy Catalent For $16.5 Billion -- MarketWatch

5. Feb. 2024, 11:08 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk: Manufacturing Sites Are in Italy, Belgium and US

5. Feb. 2024, 11:08 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Buys Sites From Novo Holdings as Part of Novo Holdings' Deal to Buy Catalent

5. Feb. 2024, 11:06 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Agrees to Buy Three Manufacturing Sites For Upfront Payment of $11 Bln

5. Feb. 2024, 11:03 UTC

Akquisitionen, Fusionen, Übernahmen

Catalent: Merger Is Expected to Close Towards the End of Calendar Yr 2024 >CTLT

5. Feb. 2024, 11:02 UTC

Akquisitionen, Fusionen, Übernahmen

Catalent: Of Co's More Than 50 Global Sites, Novo Holdings Intends to Sell Three Catalent Fill-Finish Sites and Related Assets Acquired in Merger to Novo Nordisk >CTLT

Peer-Vergleich

Kursveränderung

Catalent Inc Prognose

Kursziel

By TipRanks

7.55% Vorteil

12-Monats-Prognose

Durchschnitt 59.38 USD  7.55%

Hoch 63.5 USD

Tief 47 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Catalent Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

5 ratings

1

Buy

3

Halten

1

Sell

Technischer Score

By Trading Central

54.96 / 55.94Unterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

108 / 370 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Catalent Inc

Catalent, Inc. provides delivery technologies, and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.